MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC

NSCLC Clinical Trial

— Seagull  

Official title:

Minimal Residual Disease (MRD)-Guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB Non-small Cell Lung Cancer (NSCLC): a Randomized Controlled Phase II Study (Seagull)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05286957
• Other study ID #: L2021-Y471
• Status: Recruiting
• Phase: Phase 2
• Start date: June 20, 2022
• Est. completion date: June 1, 2027

Study information

• Verified date: March 2023
• Source: The First Affiliated Hospital of Zhengzhou University
• Contact: Feng Li, MD
• Phone: +8615838222689
• Email: LF_0604[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Seagull is a phase Ⅱ study designed to investigate the efficacy and safety of MRD-guided adjuvant tislelizumab and chemotherapy vs adjuvant tislelizumab and chemotherapy in patients with resectable NSCLC

Description:

In the phase II trial, the efficacy and safety of MRD-guided adjuvant tislelizumab and chemotherapy will be compared with that of standard adjuvant tislelizumab and chemotherapy in patients with resectable NSCLC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: June 1, 2027
• Est. primary completion date: June 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Patient with age = 18 years old, gender is not limited.

2. Histologically confirmed primary NSCLC, postoperative stage is IIA, IIB, IIIA or T3N2IIIB.

3. Receiving complete resection

4. Paraffin-embedded sections (10-15 pieces) or fresh frozen tissue are required.

5. ECOG score of 0 or 1.

6. Females of childbearing age should take appropriate contraceptive measures from screening to 3 months after discontinuation of study treatment and should not breastfeed. The pregnancy test was negative before starting dosing.

7. Male patients should use barrier contraception from screening to 3 months after discontinuation of study treatment.

8. The subjects themselves participated voluntarily and signed the informed consent in writing.

Exclusion Criteria:

1. The patient has received immune checkpoint inhibitors such as anti-PD-1, PD-L1 or CTLA-4, other immunotherapy or systemic immune modulators (including but not limited to interferon, IL-2 and TNF etc).

2. Histopathology with small cell or large cell endocrine tumor component.

3. Harboring EGFR sensitizing mutation or ALK gene translocation

4. History of other malignant tumors, except for non-melanoma skin cancer, carcinoma in situ or other solid tumors that have been effectively treated, and no evidence of any disease for >5 years after the last treatment.

5. At the start of the study treatment, there are residual toxicities of the previous treatment that are greater than CTCAE 1 and have not been alleviated, except for alopecia and grade 2 neurotoxicity caused by previous chemotherapy.

6. Any serious or uncontrolled systemic disease, including uncontrolled high blood pressure, active bleeding, active infection including hepatitis B, C, HIV, etc., which the investigator considers unsuitable to participate in the study or affect the trial program compliance.

7. History of ILD, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, or any evidence of clinically active interstitial lung disease

8. Insufficient bone marrow reserve or organ function.

9. History of hypersensitivity reactions to any active or inactive ingredient of tislelizumab or to drugs that are chemically similar to tislelizumab or in the same class of tislelizumab.

10. Patients who, in the judgment of the investigator, may not comply with the procedures and requirements of the study.

11. Patients who, in the investigator's judgment, have any condition that compromises patient safety or interferes with the evaluation of the study.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• NSCLC

Intervention

Drug:
• adjuvant tislelizumab and chemotherapy for MRD+ patients
MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+ adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)
• adjuvant tislelizumab and chemotherapy for MRD+ patients
patients receive adjuvant tislelizumab and chemotherapy regardless of MRD status
• adjuvant chemotherapy for MRD- patients
MRD- patients just be recommended receive adjuvant chemotherapy untill be detected cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion, limited to =4 cycles

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Zhengzhou University,	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Zhengzhou University	BeiGene

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	2-year PFS rate	Progression-free survival (per RECIST 1.1) is defined as the time from the starting date of study drug to the date of first documentation of disease progression or death, whichever occurs first. Subjects who do not have disease progression will be censored at their last valid tumor assessment. PFS rate at 1 year as estimated by Kaplan-Meier method.	up to 36 months after enrollment or study close
Secondary	Percentage of patients changed from MRD+ to MRD- after treatment with tislelizumab for 6 months,12 months	Percentage of patients changed from MRD+ to MRD- after treatment with Tislelizumab for 9 months,12months	At the end of Cycle 8(each cycle is 21 days)?Cycle 16 (each cycle is 21 days)